DDInter472 DDInter1628
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Danazol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) downregulates {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) upregulates {v} (Gene) GLRX
GLRX {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) upregulates {v} (Gene) ARID4B
ARID4B {u} (Gene) is regulated by {v} (Gene) STK16
STK16 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Danazol {u} (Compound) downregulates {v} (Gene) CDC45
CDC45 {u} (Gene) is regulated by {v} (Gene) PLK3
PLK3 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Danazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Danazol (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Danazol (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Ruxolitinib (Compound)
Danazol (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Ruxolitinib (Compound)
Danazol (Compound) upregulates GLRX (Gene) and GLRX (Gene) is downregulated by Ruxolitinib (Compound)
Danazol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Danazol (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Danazol (Compound) upregulates ARID4B (Gene) and ARID4B (Gene) is regulated by STK16 (Gene) and STK16 (Gene) is bound by Ruxolitinib (Compound)
Danazol (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Danazol (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is regulated by PLK3 (Gene) and PLK3 (Gene) is bound by Ruxolitinib (Compound)